Learn languages naturally with fresh, real content!

Popular Topics
Explore By Region
China approved Libevitug, a first-of-its-kind treatment for chronic hepatitis D, developed by Huahui Health.
China has approved Libevitug, a first-of-its-kind monoclonal antibody treatment for chronic hepatitis D, developed by Beijing-based Huahui Health.
The National Medical Products Administration granted conditional approval for adults with the disease, including those with compensated cirrhosis.
The drug blocks the PreS1 domain on the hepatitis B and D virus, preventing liver cell entry—critical since HDV depends on HBV to replicate.
Clinical trials showed a 44.1% combined response rate and 60% virological response at 48 weeks.
The development, rooted in a 2012 discovery of the virus receptor, reflects a rare full-chain innovation journey from basic science to market.
The approval is part of a record 76 innovative drugs approved in China in 2025, most now covered by national reimbursement, signaling growing domestic capabilities in biopharmaceutical development.
China aprobó Libevitug, un primer tratamiento de su tipo para la hepatitis D crónica, desarrollado por Huahui Health.